US12472183B2 - Anti-ischemic compositions - Google Patents

Anti-ischemic compositions

Info

Publication number
US12472183B2
US12472183B2 US17/633,147 US202017633147A US12472183B2 US 12472183 B2 US12472183 B2 US 12472183B2 US 202017633147 A US202017633147 A US 202017633147A US 12472183 B2 US12472183 B2 US 12472183B2
Authority
US
United States
Prior art keywords
organ
kda
composition
tissue
erythrocruorin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US17/633,147
Other versions
US20220354850A1 (en
Inventor
Bengt Fagrell
Jeffrey G. Parker
Nils U. Olsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seraphim Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US17/633,147 priority Critical patent/US12472183B2/en
Publication of US20220354850A1 publication Critical patent/US20220354850A1/en
Priority to US19/369,023 priority patent/US20260048057A1/en
Application granted granted Critical
Publication of US12472183B2 publication Critical patent/US12472183B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Definitions

  • compositions for use in medicine as anti-ischemic organ or tissue storage or perfusion solutions.
  • Tissue ischemia is one of the most common causes of morbidity and mortality, and is a major factor in a significant number of donor organs going unused.
  • Current organ storage, preservation and perfusion solutions lack the oxygen carrying capacity of blood.
  • Transplantation surgery involving transportation of the graft tissue or organ currently uses hypothermic preservation techniques (e.g., the tissue or organ is stored in a chest of ice).
  • hypothermic preservation techniques e.g., the tissue or organ is stored in a chest of ice.
  • prolonged periods of cold ischemia increase the risk of organ dysfunction and reduce long-term survival.
  • adenosine triphosphate ATP
  • ATP adenosine triphosphate
  • STEEN SolutionTM Xvivo Perfusion AB Corporation, Sweden
  • ischemia reperfusion injury occurs when the blood supply is blocked for a period of time, such as during ex vivo cold storage, shipping from donor to recipient, or machine perfusion with a non-oxygen carrying medium. IRI reduces the bioactivity of 5,6,7,8-tetrahydrobiopterin (BH4).
  • BH4 is a cofactor of endothelial Nitric Oxide Synthase (eNOS) in the production of nitric oxide.
  • compositions described herein can be applied in medicinal applications such as transplantation and surgical interventions that do not include transplantation.
  • compositions comprising: a purified erythrocruorin; and 5-methyltetrahydrofolate, 5-formyltetrahydrofolate, 5,6,7,8-tetrahydrobiopterin, or a combination thereof.
  • poly(ethylene glycol) is covalently attached to the purified erythrocruorin.
  • kits comprising a composition provided herein.
  • compositions for use in medicine as an anti-ischemic organ storage and perfusion solution include: an erythrocruorin (e.g., a purified erythrocruorin); and 5-methyltetrahydrofolate, 5-formyltetrahydrofolate, 5,6,7,8-tetrahydrobiopterin, or a combination thereof.
  • Erythrocruorin is a large acellular Oxygen (O 2 ) Carrying Protein Complex (OCPC) found in organisms such as annelids (e.g., polychaeta, oligochaete (including earthworms, i.e.
  • Lumbricus terrestris Lumbricus terrestris
  • arthropods e.g., chilicerata, crustacean, or tracheata
  • the erythrocruorin of Lumbricus terrestris is an OCPC having a molecular mass over 3.0 million Da (e.g., over 3.5 million Da, e.g., about 3.6 million Da, e.g., about 3.5 million Da).
  • L. terrestris 's OCPC (and other erythrocruorins) is not packaged inside a blood cell, like mammalian hemoglobin is. Instead, it floats freely in the liquid that flows through L. terrestris 's vascular system.
  • compositions comprising: a purified erythrocruorin; and 5-methyltetrahydrofolate, 5-formyltetrahydrofolate, 5,6,7,8-tetrahydrobiopterin, or a combination thereof.
  • the compositions comprise a purified erythrocruorin, 5-methyltetrahydrofolate, 5-formyltetrahydrofolate, and 5,6,7,8-tetrahydrobiopterin.
  • the composition is a solid, e.g., a powder.
  • the composition is a paste.
  • the composition is a Bingham plastic.
  • the composition is a freeze-dried powder.
  • the composition is a liquid.
  • the composition further comprises a liquid vehicle.
  • the vehicle is an aqueous vehicle.
  • the compositions comprise: a purified erythrocruorin; 5-methyltetrahydrofolate, 5-formyltetrahydrofolate, and 5,6,7,8-tetrahydrobiopterin. In some embodiments, the compositions comprise: a purified erythrocruorin; 5-methyltetrahydrofolate, and 5-formyltetrahydrofolate. In some embodiments, the compositions comprise: a purified erythrocruorin; 5-methyltetrahydrofolate, and 5,6,7,8-tetrahydrobiopterin.
  • the compositions comprise: a purified erythrocruorin; 5-formyltetrahydrofolate, and 5,6,7,8-tetrahydrobiopterin. In some embodiments, the compositions comprise: a purified erythrocruorin; and 5-methyltetrahydrofolate. In some embodiments, the compositions comprise: a purified erythrocruorin; and 5-formyltetrahydrofolate. In some embodiments, the compositions comprise: a purified erythrocruorin; and 5,6,7,8-tetrahydrobiopterin.
  • the purified erythrocruorin is a purified annelid erythrocruorin (e.g., a polychaeta erythrocruorin, an oligochaete erythrocruorin (including earthworm, i.e. Lumbricus terrestris ), or a hirudinea erythrocruorin.
  • the purified erythrocruorin is a purified arthropod erythrocruorin.
  • the purified erythrocruorin is a purified insect erythrocruorin.
  • the purified erythrocruorin is a purified Lumbricus terrestris erythrocruorin.
  • the compositions provided herein include a combination of two or more erythrocruorins independently selected from annelid erythrocruorin and arthropod erythrocruorin.
  • the composition includes a purified Lumbricus terrestris erythrocruorin and 5-methyltetrahydrofolate, 5-formyltetrahydrofolate, 5,6,7,8-tetrahydrobiopterin, or a combination thereof.
  • the composition includes a purified Lumbricus terrestris erythrocruorin and 5-methyltetrahydrofolate.
  • the composition includes a purified Lumbricus terrestris erythrocruorin and 5-formyltetrahydrofolate.
  • the composition includes a purified Lumbricus terrestris erythrocruorin and 5,6,7,8-tetrahydrobiopterin.
  • poly(ethylene glycol) is covalently attached to the purified erythrocruorin.
  • the poly(ethylene glycol) has a molecular weight of about 100 Da to about 60 kDa. In some embodiments, the poly(ethylene glycol) has a molecular weight of about 100 Da to about 200 Da, about 200 Da to about 400 Da, about 400 Da to about 600 Da, about 600 Da to about 800 Da, about 800 Da to about 1 kDa, about 1 kDa to about 2 kDa, about 2 kDa to about 4 kDa, about 4 kDa to about 6 kDa, about 6 kDa to about 8 kDa, about 8 kDa to about 10 kDa, about 10 kDa to about 20 kDa, about 20 kDa to about 30 kDa, about 30 kDa to about 40 kDa, about 40 kDa to about 50 kDa, or about 50 kDa to
  • the poly(ethylene glycol) has a molecular weight of about 100 Da, 200 Da, 400 Da, 600 Da, 800 Da, 1 kDa, 2 kDa, 3 kDa, 4 kDa, 5 kDa, 6 kDa, 7 kDa, 8 kDa, 9 kDa, 10 kDa, 20 kDa, 30 kDa, 40 kDa, 50 kDa, or 60 kDa, or any range there between.
  • the poly(ethylene glycol) has a molecular weight of about 1 kDa to about 10 kDa, e.g., about 4 kDa to about 6 kDa, e.g., about 5 kDa,
  • the composition is a pharmaceutical composition.
  • the pharmaceutical composition includes one or more pharmaceutically acceptable excipients.
  • the subject, tissue, organ, or organ cell is of a mammalian origin. In some embodiments, the subject, tissue, organ, or organ cell is of a human, canine, feline, bovine, ovine, or porcine origin. In some embodiments, the subject, tissue, organ, or organ cell is of a human origin.
  • the tissue, organ, organ cell, or tissue substitute is: a lung, liver, or heart tissue; a lung, liver, or heart organ; or a lung, liver, or heart cell.
  • the tissue, organ, organ cell, or tissue substitute is: a lung, liver, vessel, or heart tissue; a lung, liver, vessel, or heart organ; a lung, liver, vessel, or heart cell; or a lung, liver, vessel, or heart substitute (i.e. a substitute tissue, substitute organ, or substitute cell).
  • the tissue, organ, organ cell, or tissue substitute is a lung tissue, a lung organ, or a lung cell.
  • the tissue, organ, organ cell, or tissue substitute is a vessel, a vessel cell, or a vessel substitute.
  • the tissue substitute is a lung, liver, vessel, or heart tissue substitute.
  • the organ is a lung, liver, vessel, or heart.
  • the tissue, organ, organ cell, or tissue substitute is a tissue. In some embodiments, the tissue, organ, organ cell, or tissue substitute is an organ. In some embodiments, the tissue, organ, organ cell, or tissue substitute is an organ cell. In some embodiments, the tissue, organ, organ cell, or tissue substitute is a tissue substitute.
  • the tissue substitute is a biomaterial or composite scaffolded for, e.g., lung or cardiac tissue engineering, perfusable patches (grafts), or hearts (including other organs (e.g., lung) or grafts), made with or without 3-D printing or nano technology.
  • the methods described herein are performed at about 0-39° C. In some embodiments, these methods are performed at about 10-39° C. In some embodiments, these methods are performed at about 5-15° C. In some embodiments, these methods are performed at about 10-25° C. In some embodiments, these methods are performed at about 15-25° C. In some embodiments, these methods are performed at about 15-37° C. In some embodiments, these methods are performed at about 25-39° C. In some embodiments, these methods are performed at about 25-37° C. In some embodiments, these methods are performed at about 35-39° C. In some embodiments, these methods are performed at about 37-39° C. In some embodiments, these methods are performed at about 0° C.
  • these methods are performed at about 5° C. In some embodiments, these methods are performed at about 37° C. In some embodiments, these methods are performed at about 10° C. In some embodiments, these methods are performed at about 15° C. In some embodiments, these methods are performed at about 20° C. In some embodiments, these methods are performed at about 25° C. In some embodiments, these methods are performed at about 30° C. In some embodiments, these methods are performed at about 35° C. In some embodiments, these methods are performed at about 36° C. In some embodiments, these methods are performed at about 37° C. In some embodiments, these methods are performed at about 38° C. In some embodiments, these methods are performed at about 39° C.
  • the compositions provided herein can remain in an oxygenated state by circulating the composition through an oxygenator pump mechanism connected to an extracorporeal tissue, organ, organ cell, or tissue substitute.
  • the tissue, organ, organ cell, or tissue substitute can thereby also remain in an oxygenated state when in contact with such circulating composition.
  • the compositions can be used alone or in combination with standard perfusion solutions, colloids, crystalloids, plasma expanders, e.g., albumin, volume expanders, e.g., Voluven, and isotonic large-volume fluid replacement solutions, e.g., Ringer's Lactate or Ringer's Acetate solutions.
  • kits comprising a composition provided herein.
  • the Oxygen Carrying Protein Complex (OCPC) is isolated from terrestrial earthworms (nightcrawlers, a.k.a. Lumbricus terrestris ) and purified by tangential-flow filtration following the procedure described by J. P. Elmer in Life Sciences, 2012, 91, 852-9. Approximately 10 g of OCPC is isolated per 1,000 worms. The isolated OCPC is stored as a liquid solution, or lyophilized to a powder that can be reconstituted as a liquid.
  • OCPC Oxygen Carrying Protein Complex
  • the isolated OCPC of Example 1 is combined with micronutrient(s).
  • the isolated OCPC is combined with 0.001 to 500 ⁇ mol/L 5-methyltetrahydrofolate and 0.001 to 500 ⁇ mol/L 5,6,7,8-tetrahydrobiopterin.
  • the resulting mixture is stored as a liquid, reduced to a paste, or lyophilized to a powder that can be reconstituted as a liquid.
  • the isolated OCPC of Example 1 is combined with micronutrient(s).
  • the isolated OCPC is combined with 0.001 to 500 ⁇ mol/L 5-formyltetrahydrofolate and 0.001 to 500 ⁇ mol/L 5,6,7,8-tetrahydrobiopterin.
  • the resulting mixture is stored as a liquid, reduced to a paste, or lyophilized to a powder that can be reconstituted as a liquid.
  • An organ e.g., a lung, liver or heart
  • the liquid composition of Example 2, 3, or 6 is contacted with the liquid composition of Example 2, 3, or 6 at body temperature.
  • the organ's metabolic activities are preserved while in contact with the liquid composition.
  • An organ e.g., a lung, liver or heart
  • the organ's metabolic activities are preserved while in contact with the liquid composition.
  • the isolated OCPC of Example 1 is combined with micronutrient(s).
  • the isolated OCPC is combined with 0.001 to 500 ⁇ mol/L 5-methyltetrahydrofolate, 0.001 to 500 ⁇ mol/L 5-formyltetrahydrofolate, and 0.001 to 500 ⁇ mol/L 5,6,7,8-tetrahydrobiopterin.
  • the resulting mixture is stored as a liquid, reduced to a paste, or lyophilized to a powder that can be reconstituted as a liquid.
  • compositions and methods are described herein, including the best mode known to the inventors for carrying out the present disclosure.
  • variations on these described embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing description.
  • the inventor(s) expect(s) skilled artisans to employ such variations as appropriate, and the inventor(s) intend(s) for the compositions and methods described herein to be practiced otherwise than specifically described herein. Accordingly, this disclosure includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law.
  • any combination of the above-described elements in all possible variations thereof is encompassed by the present disclosure unless otherwise indicated herein or otherwise clearly contradicted by context.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Environmental Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Described herein are compositions for use in medicine as anti-ischemic organ storage and perfusion solutions.

Description

RELATED APPLICATION
This application is a national stage entry under 35 USC 371 of international patent application no. PCT/US2020/044905, filed Aug. 4, 2020, which claims priority of U.S. Provisional Patent Application No. 62/882,912, filed Aug. 5, 2019, the entire content of each of which is incorporated herein by reference.
FIELD
Described herein are compositions for use in medicine as anti-ischemic organ or tissue storage or perfusion solutions.
BACKGROUND
Tissue ischemia is one of the most common causes of morbidity and mortality, and is a major factor in a significant number of donor organs going unused. Current organ storage, preservation and perfusion solutions lack the oxygen carrying capacity of blood. Transplantation surgery involving transportation of the graft tissue or organ currently uses hypothermic preservation techniques (e.g., the tissue or organ is stored in a chest of ice). However, prolonged periods of cold ischemia increase the risk of organ dysfunction and reduce long-term survival. During cold storage of the organ without oxygen perfusion there is a depletion of adenosine triphosphate (ATP) resulting in an intra cellular build-up of toxic substances such as adenosine, inosine and hypoxanthine as well as accumulation of cations and water within the cell causing cellular swelling. One way of alleviating some of these hazards to the organ is to machine perfuse it with a non-oxygen carrying dehydrating solution, such as STEEN Solution™ (Xvivo Perfusion AB Corporation, Sweden), which is an artificial hyper oncotic preparation containing human serum albumin and dextran. Eventually, oxygenated blood flow in the tissue or organ has to be reestablished to prevent cells from dying.
Paradoxically, reperfusion with blood drives pathophysiology and the first minutes of this process are most critical, as the first damaging and irreversible event is a burst of reactive oxygen species (ROS) produced by mitochondria. This ischemia reperfusion injury (IRI) occurs when the blood supply is blocked for a period of time, such as during ex vivo cold storage, shipping from donor to recipient, or machine perfusion with a non-oxygen carrying medium. IRI reduces the bioactivity of 5,6,7,8-tetrahydrobiopterin (BH4). BH4 is a cofactor of endothelial Nitric Oxide Synthase (eNOS) in the production of nitric oxide. With suboptimal levels of BH4, eNOS generates both nitric oxide and superoxide (O2 −), which leads to formation of hydrogen peroxide (H2O2). Thus, there remains a need for compositions and methods of addressing tissue ischemia in subjects suffering therefrom and in tissue or organs intended for transplantation.
SUMMARY
The compositions described herein can be applied in medicinal applications such as transplantation and surgical interventions that do not include transplantation.
Thus, provided herein are compositions, comprising: a purified erythrocruorin; and 5-methyltetrahydrofolate, 5-formyltetrahydrofolate, 5,6,7,8-tetrahydrobiopterin, or a combination thereof. In some embodiments, poly(ethylene glycol) is covalently attached to the purified erythrocruorin.
Also provided herein are methods of storing a tissue, an organ, an organ cell, or a tissue substitute in need thereof, comprising storing the tissue, organ, organ cell, or tissue substitute, while concurrently contacting the tissue, organ, organ cell, or tissue substitute with a composition provided herein.
Also provided herein are methods of mitigating ischemia in a tissue, an organ, an organ cell, or a tissue substitute in need thereof, comprising contacting the tissue, organ, organ cell, or tissue substitute with a composition provided herein.
Also provided herein are methods of treating ischemia in a subject in need thereof, comprising contacting an ischemic tissue, organ, organ cell, or tissue substitute in the subject with a composition provided herein.
Also provided herein are kits, comprising a composition provided herein.
DETAILED DESCRIPTION
Described herein are compositions for use in medicine as an anti-ischemic organ storage and perfusion solution. The compositions provided herein include: an erythrocruorin (e.g., a purified erythrocruorin); and 5-methyltetrahydrofolate, 5-formyltetrahydrofolate, 5,6,7,8-tetrahydrobiopterin, or a combination thereof. Erythrocruorin is a large acellular Oxygen (O2) Carrying Protein Complex (OCPC) found in organisms such as annelids (e.g., polychaeta, oligochaete (including earthworms, i.e. Lumbricus terrestris), or hirudinea) and arthropods (e.g., chilicerata, crustacean, or tracheata). The erythrocruorin of Lumbricus terrestris, for example, is an OCPC having a molecular mass over 3.0 million Da (e.g., over 3.5 million Da, e.g., about 3.6 million Da, e.g., about 3.5 million Da). L. terrestris's OCPC (and other erythrocruorins) is not packaged inside a blood cell, like mammalian hemoglobin is. Instead, it floats freely in the liquid that flows through L. terrestris's vascular system.
Thus, provided herein are compositions, comprising: a purified erythrocruorin; and 5-methyltetrahydrofolate, 5-formyltetrahydrofolate, 5,6,7,8-tetrahydrobiopterin, or a combination thereof. In some embodiments, the compositions comprise a purified erythrocruorin, 5-methyltetrahydrofolate, 5-formyltetrahydrofolate, and 5,6,7,8-tetrahydrobiopterin. In some embodiments, the composition is a solid, e.g., a powder. In some embodiments, the composition is a paste. In some embodiments, the composition is a Bingham plastic. In some embodiments, the composition is a freeze-dried powder. In some embodiments, the composition is a liquid. In some embodiments, the composition further comprises a liquid vehicle. In some embodiments, the vehicle is an aqueous vehicle.
In some embodiments, the compositions comprise: a purified erythrocruorin; 5-methyltetrahydrofolate, 5-formyltetrahydrofolate, and 5,6,7,8-tetrahydrobiopterin. In some embodiments, the compositions comprise: a purified erythrocruorin; 5-methyltetrahydrofolate, and 5-formyltetrahydrofolate. In some embodiments, the compositions comprise: a purified erythrocruorin; 5-methyltetrahydrofolate, and 5,6,7,8-tetrahydrobiopterin. In some embodiments, the compositions comprise: a purified erythrocruorin; 5-formyltetrahydrofolate, and 5,6,7,8-tetrahydrobiopterin. In some embodiments, the compositions comprise: a purified erythrocruorin; and 5-methyltetrahydrofolate. In some embodiments, the compositions comprise: a purified erythrocruorin; and 5-formyltetrahydrofolate. In some embodiments, the compositions comprise: a purified erythrocruorin; and 5,6,7,8-tetrahydrobiopterin.
In some embodiments, the purified erythrocruorin is a purified annelid erythrocruorin (e.g., a polychaeta erythrocruorin, an oligochaete erythrocruorin (including earthworm, i.e. Lumbricus terrestris), or a hirudinea erythrocruorin. In some embodiments, the purified erythrocruorin is a purified arthropod erythrocruorin. In some embodiments, the purified erythrocruorin is a purified insect erythrocruorin. In some embodiments, the purified erythrocruorin is a purified Lumbricus terrestris erythrocruorin. In some embodiments, the compositions provided herein include a combination of two or more erythrocruorins independently selected from annelid erythrocruorin and arthropod erythrocruorin.
In some embodiments, the composition includes a purified Lumbricus terrestris erythrocruorin and 5-methyltetrahydrofolate, 5-formyltetrahydrofolate, 5,6,7,8-tetrahydrobiopterin, or a combination thereof.
In some embodiments, the composition includes a purified Lumbricus terrestris erythrocruorin and 5-methyltetrahydrofolate.
In some embodiments, the composition includes a purified Lumbricus terrestris erythrocruorin and 5-formyltetrahydrofolate.
In some embodiments, the composition includes a purified Lumbricus terrestris erythrocruorin and 5,6,7,8-tetrahydrobiopterin.
In some embodiments, poly(ethylene glycol) is covalently attached to the purified erythrocruorin. In some embodiments, the poly(ethylene glycol) has a molecular weight of about 100 Da to about 60 kDa. In some embodiments, the poly(ethylene glycol) has a molecular weight of about 100 Da to about 200 Da, about 200 Da to about 400 Da, about 400 Da to about 600 Da, about 600 Da to about 800 Da, about 800 Da to about 1 kDa, about 1 kDa to about 2 kDa, about 2 kDa to about 4 kDa, about 4 kDa to about 6 kDa, about 6 kDa to about 8 kDa, about 8 kDa to about 10 kDa, about 10 kDa to about 20 kDa, about 20 kDa to about 30 kDa, about 30 kDa to about 40 kDa, about 40 kDa to about 50 kDa, or about 50 kDa to about 60 kDa. In some embodiments, the poly(ethylene glycol) has a molecular weight of about 100 Da, 200 Da, 400 Da, 600 Da, 800 Da, 1 kDa, 2 kDa, 3 kDa, 4 kDa, 5 kDa, 6 kDa, 7 kDa, 8 kDa, 9 kDa, 10 kDa, 20 kDa, 30 kDa, 40 kDa, 50 kDa, or 60 kDa, or any range there between. In some embodiments, the poly(ethylene glycol) has a molecular weight of about 1 kDa to about 10 kDa, e.g., about 4 kDa to about 6 kDa, e.g., about 5 kDa,
In some embodiments, the composition is a pharmaceutical composition. In some embodiments, the pharmaceutical composition includes one or more pharmaceutically acceptable excipients.
Also provided herein are methods of storing tissue, an organ, or an organ cell, comprising storing the tissue, organ or organ cell while concurrently contacting the tissue, organ, or organ cell with a composition provided herein.
Also provided herein are methods of mitigating ischemia in tissue, an organ, or an organ cell in need thereof, comprising contacting the tissue, organ, or organ cell with a composition provided herein.
Also provided herein are methods of preserving tissue, an organ, or an organ cell in need thereof, comprising contacting the tissue, organ, or organ cell with a composition provided herein.
Also provided herein are methods of treating ischemia in a subject in need thereof, comprising contacting ischemic tissue in the subject with a composition provided herein.
In some embodiments of these methods, the subject, tissue, organ, or organ cell is of a mammalian origin. In some embodiments, the subject, tissue, organ, or organ cell is of a human, canine, feline, bovine, ovine, or porcine origin. In some embodiments, the subject, tissue, organ, or organ cell is of a human origin.
In some embodiments, the tissue, organ, organ cell, or tissue substitute is: a lung, liver, or heart tissue; a lung, liver, or heart organ; or a lung, liver, or heart cell. In some embodiments, the tissue, organ, organ cell, or tissue substitute is: a lung, liver, vessel, or heart tissue; a lung, liver, vessel, or heart organ; a lung, liver, vessel, or heart cell; or a lung, liver, vessel, or heart substitute (i.e. a substitute tissue, substitute organ, or substitute cell). In some embodiments, the tissue, organ, organ cell, or tissue substitute is a lung tissue, a lung organ, or a lung cell. In some embodiments, the tissue, organ, organ cell, or tissue substitute is a vessel, a vessel cell, or a vessel substitute. In some embodiments, the tissue substitute is a lung, liver, vessel, or heart tissue substitute. In some embodiments, the organ is a lung, liver, vessel, or heart.
In some embodiments, the tissue, organ, organ cell, or tissue substitute is a tissue. In some embodiments, the tissue, organ, organ cell, or tissue substitute is an organ. In some embodiments, the tissue, organ, organ cell, or tissue substitute is an organ cell. In some embodiments, the tissue, organ, organ cell, or tissue substitute is a tissue substitute.
In some embodiments, the tissue substitute is a biomaterial or composite scaffolded for, e.g., lung or cardiac tissue engineering, perfusable patches (grafts), or hearts (including other organs (e.g., lung) or grafts), made with or without 3-D printing or nano technology.
In some embodiments, the methods described herein are performed at about 0-39° C. In some embodiments, these methods are performed at about 10-39° C. In some embodiments, these methods are performed at about 5-15° C. In some embodiments, these methods are performed at about 10-25° C. In some embodiments, these methods are performed at about 15-25° C. In some embodiments, these methods are performed at about 15-37° C. In some embodiments, these methods are performed at about 25-39° C. In some embodiments, these methods are performed at about 25-37° C. In some embodiments, these methods are performed at about 35-39° C. In some embodiments, these methods are performed at about 37-39° C. In some embodiments, these methods are performed at about 0° C. In some embodiments, these methods are performed at about 5° C. In some embodiments, these methods are performed at about 37° C. In some embodiments, these methods are performed at about 10° C. In some embodiments, these methods are performed at about 15° C. In some embodiments, these methods are performed at about 20° C. In some embodiments, these methods are performed at about 25° C. In some embodiments, these methods are performed at about 30° C. In some embodiments, these methods are performed at about 35° C. In some embodiments, these methods are performed at about 36° C. In some embodiments, these methods are performed at about 37° C. In some embodiments, these methods are performed at about 38° C. In some embodiments, these methods are performed at about 39° C.
In some embodiments, the compositions provided herein can remain in an oxygenated state by circulating the composition through an oxygenator pump mechanism connected to an extracorporeal tissue, organ, organ cell, or tissue substitute. The tissue, organ, organ cell, or tissue substitute can thereby also remain in an oxygenated state when in contact with such circulating composition. In some embodiments, the compositions can be used alone or in combination with standard perfusion solutions, colloids, crystalloids, plasma expanders, e.g., albumin, volume expanders, e.g., Voluven, and isotonic large-volume fluid replacement solutions, e.g., Ringer's Lactate or Ringer's Acetate solutions.
Also provided herein are kits, comprising a composition provided herein.
EXAMPLES
The following examples illustrate the compositions and uses described herein.
Example 1: Preparation of Erythrocruorin Compositions
The Oxygen Carrying Protein Complex (OCPC) is isolated from terrestrial earthworms (nightcrawlers, a.k.a. Lumbricus terrestris) and purified by tangential-flow filtration following the procedure described by J. P. Elmer in Life Sciences, 2012, 91, 852-9. Approximately 10 g of OCPC is isolated per 1,000 worms. The isolated OCPC is stored as a liquid solution, or lyophilized to a powder that can be reconstituted as a liquid.
Example 2: Preparation of Erythrocruorin Compositions Including Micronutrients
The isolated OCPC of Example 1 is combined with micronutrient(s). Thus, the isolated OCPC is combined with 0.001 to 500 μmol/L 5-methyltetrahydrofolate and 0.001 to 500 μmol/L 5,6,7,8-tetrahydrobiopterin. The resulting mixture is stored as a liquid, reduced to a paste, or lyophilized to a powder that can be reconstituted as a liquid.
Example 3: Preparation of Erythrocruorin Compositions Including Micronutrients
The isolated OCPC of Example 1 is combined with micronutrient(s). Thus, the isolated OCPC is combined with 0.001 to 500 μmol/L 5-formyltetrahydrofolate and 0.001 to 500 μmol/L 5,6,7,8-tetrahydrobiopterin. The resulting mixture is stored as a liquid, reduced to a paste, or lyophilized to a powder that can be reconstituted as a liquid.
Example 4: Preservation of Organ or Tissue
An organ (e.g., a lung, liver or heart) is contacted with the liquid composition of Example 2, 3, or 6 at body temperature. The organ's metabolic activities are preserved while in contact with the liquid composition.
Example 5: Preservation of Organ or Tissue
An organ (e.g., a lung, liver or heart) is contacted with the liquid composition of Example 3 at body temperature. The organ's metabolic activities are preserved while in contact with the liquid composition.
Example 6: Preparation of Erythrocruorin Compositions Including Micronutrients
The isolated OCPC of Example 1 is combined with micronutrient(s). Thus, the isolated OCPC is combined with 0.001 to 500 μmol/L 5-methyltetrahydrofolate, 0.001 to 500 μmol/L 5-formyltetrahydrofolate, and 0.001 to 500 μmol/L 5,6,7,8-tetrahydrobiopterin. The resulting mixture is stored as a liquid, reduced to a paste, or lyophilized to a powder that can be reconstituted as a liquid.
Although preferred embodiments have been described in this specification and the accompanying drawings, it will be appreciated that a number of variations and modifications may suggest themselves to those skilled in the pertinent arts. Thus, the scope of the present disclosure is not limited to the specific embodiments and examples described herein, but should be deemed to encompass alternative embodiments and equivalents.
Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present disclosure. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the disclosure are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.
The terms “a,” “an,” “the” and similar referents used in the context of describing the compositions and methods described herein (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein is intended merely to better illuminate the present disclosure and does not pose a limitation on the scope of the disclosure otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the use of the compositions and methods provided herein.
Groupings of alternative elements or embodiments of the compositions and methods disclosed herein are not to be construed as limitations. Each group member may be referred to and claimed individually or in any combination with other members of the group or other elements found herein. It is anticipated that one or more members of a group may be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the specification is deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.
Certain embodiments of these compositions and methods are described herein, including the best mode known to the inventors for carrying out the present disclosure. Of course, variations on these described embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventor(s) expect(s) skilled artisans to employ such variations as appropriate, and the inventor(s) intend(s) for the compositions and methods described herein to be practiced otherwise than specifically described herein. Accordingly, this disclosure includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the present disclosure unless otherwise indicated herein or otherwise clearly contradicted by context.
Furthermore, numerous references have been made to patents and printed publications throughout this specification. Each of the above-cited references and printed publications are individually incorporated herein by reference in their entirety.
In closing, it is to be understood that the embodiments of the compositions and methods disclosed herein are illustrative of the principles of the present disclosure. Other modifications that may be employed are within the scope of the present disclosure. Thus, by way of example, but not of limitation, alternative configurations of the present disclosure may be utilized in accordance with the teachings herein. Accordingly, the present disclosure is not limited to that precisely as shown and described.

Claims (13)

What is claimed is:
1. A composition, comprising:
a purified erythrocruorin; and
5-methyltetrahydrofolate, 5-formyltetrahydrofolate, or 5-methyltetrahydrofolate and 5-formyltetrahydrofolate,
wherein the composition optionally comprises 5,6,7,8-tetrahydrobiopterin.
2. The composition of claim 1, wherein the composition is a powder.
3. The composition of claim 1, wherein the composition is a liquid.
4. The composition of claim 1, wherein the purified erythrocruorin is a purified annelid erythrocruorin.
5. The composition of claim 1, wherein the purified erythrocruorin is a purified arthropod erythrocruorin.
6. The composition of claim 1, wherein the purified erythrocruorin is a purified insect erythrocruorin.
7. The composition of claim 1, wherein the purified erythrocruorin is a purified Lumbricus terrestris erythrocruorin.
8. The composition of claim 1, wherein poly(ethylene glycol) is covalently attached to the purified erythrocruorin.
9. The composition of claim 8, wherein the poly(ethylene glycol) has a molecular weight of about 100 Da to about 60 kDa.
10. The composition of claim 8, wherein the poly(ethylene glycol) has a molecular weight of about 100 Da, 200 Da, 400 Da, 600 Da, 800 Da, 1 kDa, 2 kDa, 4 kDa, 6 kDa, 8 kDa, 10 kDa, 20 kDa, 30 kDa, 40 kDa, 50 kDa, or 60 kDa.
11. A kit, comprising the composition of claim 1.
12. A method of storing tissue, an organ, or an organ cell, comprising storing the tissue, organ or organ cell while concurrently contacting the tissue, organ, or organ cell with the composition of claim 1.
13. A method of preserving tissue, an organ, or an organ cell in need thereof, comprising contacting the tissue, organ, or organ cell with the composition of claim 1.
US17/633,147 2019-08-05 2020-08-04 Anti-ischemic compositions Active 2042-12-16 US12472183B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US17/633,147 US12472183B2 (en) 2019-08-05 2020-08-04 Anti-ischemic compositions
US19/369,023 US20260048057A1 (en) 2019-08-05 2025-10-24 Anti-ischemic compositions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962882912P 2019-08-05 2019-08-05
PCT/US2020/044905 WO2021026169A1 (en) 2019-08-05 2020-08-04 Anti-ischemic compositions
US17/633,147 US12472183B2 (en) 2019-08-05 2020-08-04 Anti-ischemic compositions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/044905 A-371-Of-International WO2021026169A1 (en) 2019-08-05 2020-08-04 Anti-ischemic compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US19/369,023 Continuation US20260048057A1 (en) 2019-08-05 2025-10-24 Anti-ischemic compositions

Publications (2)

Publication Number Publication Date
US20220354850A1 US20220354850A1 (en) 2022-11-10
US12472183B2 true US12472183B2 (en) 2025-11-18

Family

ID=74504070

Family Applications (2)

Application Number Title Priority Date Filing Date
US17/633,147 Active 2042-12-16 US12472183B2 (en) 2019-08-05 2020-08-04 Anti-ischemic compositions
US19/369,023 Pending US20260048057A1 (en) 2019-08-05 2025-10-24 Anti-ischemic compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
US19/369,023 Pending US20260048057A1 (en) 2019-08-05 2025-10-24 Anti-ischemic compositions

Country Status (2)

Country Link
US (2) US12472183B2 (en)
WO (1) WO2021026169A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021026169A1 (en) 2019-08-05 2021-02-11 Seraphim Therapeutics, Inc. Anti-ischemic compositions
WO2024103022A1 (en) * 2022-11-10 2024-05-16 Ohio State Innovation Foundation Polydopamine encapsulated materials and methods of making and using thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001056551A2 (en) * 2000-01-31 2001-08-09 University Of Zurich Method and formulation for treatment of vasoconstriction
US20100209902A1 (en) 2007-08-09 2010-08-19 Hemarina Sa Use of a Globin, a Globin Protomer or an Extracellular Hemoglobin for the Preservation of Organs, Tissues, Organ and Tissue Cells and Cell Cultures
US20140113274A1 (en) 2011-05-31 2014-04-24 Hemarina Organ-preserving composition and uses
US20150190343A1 (en) 2012-06-05 2015-07-09 Hemarina Annelid haemoglobin lyophilisation process
WO2021026169A1 (en) 2019-08-05 2021-02-11 Seraphim Therapeutics, Inc. Anti-ischemic compositions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001056551A2 (en) * 2000-01-31 2001-08-09 University Of Zurich Method and formulation for treatment of vasoconstriction
US20100209902A1 (en) 2007-08-09 2010-08-19 Hemarina Sa Use of a Globin, a Globin Protomer or an Extracellular Hemoglobin for the Preservation of Organs, Tissues, Organ and Tissue Cells and Cell Cultures
US20140113274A1 (en) 2011-05-31 2014-04-24 Hemarina Organ-preserving composition and uses
US20150190343A1 (en) 2012-06-05 2015-07-09 Hemarina Annelid haemoglobin lyophilisation process
WO2021026169A1 (en) 2019-08-05 2021-02-11 Seraphim Therapeutics, Inc. Anti-ischemic compositions

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
Elmer et al., "Oxygen delivery during extreme anemia with ultra-pure earthworm hemoglobin", Life Sciences, vol. 91, No. 2, Oct. 29, 2012, pp. 852-859.
Filpula et al., Releasable PEGylation of proteins with customized linkers, Advanced Drug Delivery Reviews, 2008, 60: 29-49. (Year: 2008). *
International Search Report and Written Opinion, mailed Oct. 6, 2020, for International Application Serial No. PCT/US2020/044905 filed Aug. 4, 2020.
Jani et al., "Polyethylene Glycol Camouflaged Earthworm Hemoglobin", PLOS ONE, vol. 12, Jan. 18, 2017, pp. 1-22.
Maglione et al., "Prevention of lethal murine pancreas ischemia reperfusion injury is specific for tetrahydrobiopterin", Transplant International, vol. 25, Jul. 17 (Jul. 17, 2012), p. 1084-1095.
Veronese et al., "PEGylation, successful approach to drug delivery," Drug Discovery Today, Nov. 2005, 10(21): 1451-1458. (Year: 2005). *
Weber et al., "Nonvertebrate Hemoglobins: FUnctions and Molecular Adaptations," Physiological Reviews, Apr. 2001, 81(2): 569-628. (Year: 2001). *
Elmer et al., "Oxygen delivery during extreme anemia with ultra-pure earthworm hemoglobin", Life Sciences, vol. 91, No. 2, Oct. 29, 2012, pp. 852-859.
Filpula et al., Releasable PEGylation of proteins with customized linkers, Advanced Drug Delivery Reviews, 2008, 60: 29-49. (Year: 2008). *
International Search Report and Written Opinion, mailed Oct. 6, 2020, for International Application Serial No. PCT/US2020/044905 filed Aug. 4, 2020.
Jani et al., "Polyethylene Glycol Camouflaged Earthworm Hemoglobin", PLOS ONE, vol. 12, Jan. 18, 2017, pp. 1-22.
Maglione et al., "Prevention of lethal murine pancreas ischemia reperfusion injury is specific for tetrahydrobiopterin", Transplant International, vol. 25, Jul. 17 (Jul. 17, 2012), p. 1084-1095.
Veronese et al., "PEGylation, successful approach to drug delivery," Drug Discovery Today, Nov. 2005, 10(21): 1451-1458. (Year: 2005). *
Weber et al., "Nonvertebrate Hemoglobins: FUnctions and Molecular Adaptations," Physiological Reviews, Apr. 2001, 81(2): 569-628. (Year: 2001). *

Also Published As

Publication number Publication date
US20260048057A1 (en) 2026-02-19
US20220354850A1 (en) 2022-11-10
WO2021026169A1 (en) 2021-02-11

Similar Documents

Publication Publication Date Title
US20260048057A1 (en) Anti-ischemic compositions
Guibert et al. Organ preservation: current concepts and new strategies for the next decade
ES2641883T3 (en) Use of a globin, a globin protomer or an extracellular hemoglobin for the preservation of organs, tissues, or of cells of organs or tissues
CA2417331A1 (en) Transplant media comprising bnp-1
WO2001001774A1 (en) Continuous cardiac perfusion preservation with peg-hb for improved hypothermic storage
FR3038324A1 (en) METHOD FOR CRYOPRESERVATION OF THERAPEUTICALLY TARGED CELLS
EP2938186B1 (en) Organ and tissue preservation formulations with increased stability and shelf life
US5153004A (en) Freezing and thawing of erythrocytes
WO2008108549A1 (en) Method on long-term structural preservation of hemocyte utilizing cellular lyophilization technique
US5962213A (en) Compositions and methods for the preservation of living tissues
JP2024098028A (en) Compositions for transport and/or cryopreservation of cells and/or tissues
RU2396748C2 (en) Medium for storage of cells
US5879875A (en) Compositions and methods for the preservation of living tissues
AU725247B2 (en) Compositions and methods for the preservation of living tissues
WO2020077184A1 (en) Oxygenation media for ex-vivo preservation of organs and tissues
CN113892481A (en) A hydrogel for cell or tissue storage, transport and bioprinting
US6114107A (en) Composition comprising raffinose, TMAO, sodium citrate and methods for the preservation of living tissues
CN116058363A (en) A method for increasing the activity of NK cells after cryopreservation and recovery and its application
EP1736051A2 (en) Medium and method for preserving platelets, red blood cells, and other non-nucleus cells and platelets-containing composition
CA2850714C (en) Medical fluid comprising globulin and its use for preservation of harvested organs
KR100688443B1 (en) Serum-free cryopreservation solution for long-term storage of cellular artificial tissue and cryopreservation method of cellular artificial tissue using the same
Rezaei et al. Machine preservation of extremities.
KR101426804B1 (en) Platelet preserving composition, and kit for preserving platelet, and method for preserving platelet using the same
Fan et al. Experimental study on rehydration conditions of freeze-dried platelets
Yoshida et al. Heterotopic transplant of an isolated rat heart preserved for 72 h in perfluorocarbon with CO2

Legal Events

Date Code Title Description
AS Assignment

Owner name: SERAPHIM THERAPEUTICS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FAGRELL, BENGT;PARKER, JEFFREY G.;OLSSON, NILS U.;SIGNING DATES FROM 20190819 TO 20190829;REEL/FRAME:058898/0388

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION UNDERGOING PREEXAM PROCESSING

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: ALLOWED -- NOTICE OF ALLOWANCE NOT YET MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

AS Assignment

Owner name: FAGRELL, BENGT, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SERAPHIM THERAPEUTICS, INC.;REEL/FRAME:072529/0607

Effective date: 20250828

Owner name: PARKER, JEFFREY G., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SERAPHIM THERAPEUTICS, INC.;REEL/FRAME:072529/0607

Effective date: 20250828

Owner name: OLSSON, NILLS U., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SERAPHIM THERAPEUTICS, INC.;REEL/FRAME:072529/0607

Effective date: 20250828

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE